January 25, 2023 11:18 AM EST

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone

Lei Lei Wu

News Reporter

Tyler Patchen

News Reporter

The FDA’s Antimicrobial Drugs Advisory Committee voted 14-1 in favor of a limited-use indication for Cidara Therapeutics’ rezafungin, a treatment for candidemia and invasive candidiasis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone

Lei Lei Wu

News Reporter

Tyler Patchen

News Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

FDA ad­comm votes in fa­vor of new an­ti­fun­gal; De­nali gets $25M from Sanofi MS tri­al mile­stone

News Reporter

News Reporter

Sign up to read this article for free.

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone